Medical Oncology

Gandini S , Sera F , Cattaruzza MS , et al. Meta-analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 2005;41:45-60.

Dubois RW , Swetter SM , Atkins M , et al. Developing indications for the use of sentinel lymph node biopsy and adjuvant high-dose interferon alfa-2b in melanoma. Arch Dermatol. 2001;137:1217-1224.

Kim CJ , Reintgen DS , Balch CM . The new melanoma staging system. Cancer Control. 2002;9:9-15.

Buzaid AC , Ross MI , Balch CM , et al. Critical analysis of the American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol. 1997;15:1039-1051.

Kirkwood JM , Strawderman MH , Ernstoff MS , et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7-17.

Kirkwood JM , Ibrahim JG , Sondak VK , et al. High-and lowdose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol. 2000;18:2444-2458.

Kirkwood JM , Ibrahim JG , Sosman JA , et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH-QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol. 2001;19:2370-2380.

Eggermont AM , Punt CJ . Does adjuvant systemic therapy with interferon-alpha for stage II-III melanoma prolong survival? Am J Clin Dermatol. 2003;4:531-536.

Kirkwood JM , Manola J , Ibrahim J , Sondak V , Ernstoff MS , Rao U ; Eastern Cooperative Oncology Group. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res. 2004;10:1670-1677.

Hauschild A , Weichenthal M , Balda BR , et al. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate-and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol. 2003;21:2883-2888.

Hancock BW , Wheatley K , Harris S , et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study—United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon alfa-2a in high-risk resected malignant melanoma. J Clin Oncol. 2004;22:53-61.

Agarwala SS , Neuberg D , Park Y , Kirkwood JM . Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer stage I-III melanoma (E1673): a trial of the Eastern Oncology Group. Cancer. 2004;100:1692-1698.

Bystryn JC , Rudolph JL . Emerging melanoma vaccines. Expert Opin Emerg Drugs. 2005;10:393-402.

Kirkwood JM , Bender C , Agarwala S , et al. Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy. J Clin Oncol.2002;20:3703-3718.